Multivalency: Key Feature in Overcoming Drug Resistance with a Cleavable Cell-Penetrating Peptide-Doxorubicin Conjugate

被引:2
作者
Lelle, Marco [1 ,2 ,3 ]
Freidel, Christoph [1 ]
Kaloyanova, Stefka [1 ]
Muellen, Klaus [1 ]
Peneva, Kalina [1 ,2 ]
机构
[1] Max Planck Inst Polymer Res, Ackermannweg 10, D-55128 Mainz, Germany
[2] Friedrich Schiller Univ Jena, Jena Ctr Soft Matter, Inst Organ & Macromol Chem, Lessingstr 8, D-07743 Jena, Germany
[3] Univ Hosp Jena, Inst Physiol 2, Kollegiengasse 9, D-07743 Jena, Germany
关键词
Cell-penetrating peptide; Multivalency; Drug-peptide conjugate; MDR; Doxorubicin; Drug resistance; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; CANCER; DELIVERY; ANTHRACYCLINES; GLUTATHIONE; BINDING; NANOMEDICINE; RELEASE; TUMORS;
D O I
10.1007/s10989-017-9622-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multivalency is often used in biological systems, to increase affinity and specificity through avidity. This inspired us to prepare a synthetic bioconjugate that mimics natural multivalent systems. It is composed of doxorubicin and two octaarginine cell-penetrating peptides, to strengthen the electrostatic interactions between the negatively charged glycosaminoglycans of the plasma membrane and the guanidinium groups of the arginine residues. The multivalent conjugate has improved cellular uptake and cytotoxicity, compared to a peptide-drug conjugate with only one polyarginine and as a result it can overcome drug resistance in Kelly-ADR cells. The synthetic approach and the multivalent structure reported here can be used further as model systems, to gain insight into the biological interaction of cell-penetrating peptides with artificial membranes or for the preparation of more complex multimers.
引用
收藏
页码:355 / 367
页数:13
相关论文
共 52 条
[1]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[2]   Maurocalcine as a Non Toxic Drug Carrier Overcomes Doxorubicin Resistance in the Cancer Cell Line MDA-MB 231 [J].
Aroui, Sonia ;
Ram, Narendra ;
Appaix, Florence ;
Ronjat, Michel ;
Kenani, Abderraouf ;
Pirollet, Fabienne ;
De Waard, Michel .
PHARMACEUTICAL RESEARCH, 2009, 26 (04) :836-845
[3]   The role of glutathione in cancer [J].
Balendiran, GK ;
Dabur, R ;
Fraser, D .
CELL BIOCHEMISTRY AND FUNCTION, 2004, 22 (06) :343-352
[4]   Drug delivery and release systems for targeted tumor therapy [J].
Boehme, David ;
Beck-Sickinger, Annette G. .
JOURNAL OF PEPTIDE SCIENCE, 2015, 21 (03) :186-200
[5]  
Dean M, 2001, J LIPID RES, V42, P1007
[6]   REGULATION OF CELLULAR GLUTATHIONE [J].
DENEKE, SM ;
FANBURG, BL .
AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 257 (04) :L163-L173
[7]   Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters [J].
Dubikovskaya, Elena A. ;
Thorne, Steve H. ;
Pillow, Thomas H. ;
Contag, Christopher H. ;
Wender, Paul A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (34) :12128-12133
[8]   A comprehensive model for the cellular uptake of cationic cell-penetrating peptides [J].
Duchardt, Falk ;
Fotin-Mleczek, Mariola ;
Schwarz, Heinz ;
Fischer, Rainer ;
Brock, Roland .
TRAFFIC, 2007, 8 (07) :848-866
[9]   Multivalency as a Chemical Organization and Action Principle [J].
Fasting, Carlo ;
Schalley, Christoph A. ;
Weber, Marcus ;
Seitz, Oliver ;
Hecht, Stefan ;
Koksch, Beate ;
Dernedde, Jens ;
Graf, Christina ;
Knapp, Ernst-Walter ;
Haag, Rainer .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2012, 51 (42) :10472-10498
[10]   Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer [J].
Fueredia, Andras ;
Szebenyi, Kornelia ;
Toth, Szilard ;
Cserepes, Mihaly ;
Hamori, Lilla ;
Nagy, Veronika ;
Karai, Edina ;
Vajdovich, Peter ;
Imre, Timea ;
Szabo, Pal ;
Szuts, David ;
Tovari, Jozsef ;
Szakacs, Gergely .
JOURNAL OF CONTROLLED RELEASE, 2017, 261 :287-296